Argenx ((ARGX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenx (ARGX) is conducting a Phase 4 clinical study titled ‘A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC.’ The study aims to evaluate how adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) transition from intravenous immunoglobulin (IVIg) treatment to efgartigimod PH20 SC, a subcutaneous injection. This research is significant as it could offer a more convenient treatment option for CIDP patients.
The intervention being tested is efgartigimod PH20 SC, a biological treatment administered via subcutaneous injection. It is designed to replace the current IVIg treatment, potentially offering a more accessible and less invasive option for patients.
This interventional study follows a single-group model without masking, focusing on treatment as its primary purpose. Participants will transition from IVIg to efgartigimod PH20 SC, with the study assessing their adjustment over approximately 17 to 19 weeks.
The study began on December 10, 2024, with its primary completion and estimated full completion dates yet to be announced. The latest update was submitted on August 14, 2025, indicating ongoing recruitment and progress.
The market implications of this study are noteworthy. If successful, efgartigimod PH20 SC could enhance Argenx’s market position by providing a competitive alternative to existing CIDP treatments, potentially boosting investor confidence and stock performance. This development could also impact competitors in the CIDP treatment space.
The study is currently recruiting, with further updates and details accessible on the ClinicalTrials portal.